Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Must be getting late in Denmark lol
The land of no corruption.
Moods change, yet we are still here.
How much did we invest in Acadia?
Asking for a friend..
Probably explains the pre market action, or the lack of.
This never happens in Denmark!!
Too busy drinking the coolaid ! LOL
We had our unnecessary tanking last week.
But anything is possible, just not probable.
Like needing a PM trial and not getting granted AA for AD.
Devil is in the details, lots of fear mongering out there and here.
But facts are he works at SVB Securities, which is still puzzling he found a job after Lehman lol
Wrong he is Chief Administrative Officer of SVB Securities a separate entity from SVB.
Doubtful...
The flow is usually from FDA to pharma not the other way around.
But hey in this corrupt world anything is possible, like planting the participant of very dangerous drug in the FDA in order to secure the approval of other schietty drugs.
In other news:
EXCLUSIVE --> Biogen’s $BIIB Samantha Budd Haeberlein, an architect of Aduhelm, leaves company https://t.co/j6Fuqw8uNG
— Adam Feuerstein ✡️ (@adamfeuerstein) March 12, 2023
Her departure comes two weeks after Billy Dunn left the FDA.
Hey that's mean sir.
No free handouts?
Disappointed!
Teach a man how to fish comes to mind.
Anavex has been a great lesson in biotech investing thus far.
Everyone should use their own brain and judgements even when wrong.
Learning is only achieved when being wrong, via negativa!
Great catch, why is prudent to trust what comes out of the companies legally binding documents 8k/10k vs what clinicaltrials.gov a Third party organization has or does.
Well said.
Be investors!
Maybe our local medical school lecturer can apply to learn about proper distributions in the medical field.
Even if true,
We haven't used the shelf yet to my knowledge.
There are plenty of other banks not in deep shit.
So I don't see an issue here at all.
Yet here we are.
Unable to move on and away.
Glad you admit that the information we got at JP was not proper top line data.
Now the question I have left, is did IR really tell you we would have it by then?
Never I cant see your post because you are replying to someone in my ignore.
But at least you see admission of not getting proper TOP LINE DATA before JP, I wonder why IR told him/her otherwise.
And we are back lol
Yes I recall, I was speaking the revision afterward.
No new information has been gathered.
Maybe just a mood thing.
Careful there is you are starting to sound like you belive there is more than a 5 percent chance of AA.
Perhaps she was a painter before she had the disease?
A stale sandwich to some is fine food for others.
Perspective matters here in the real world.
In your post you said that you do not know of any company that has done what we have done.
In my response I said no company has been able to show results like ours and used our methodology to achieve these results.
Method, our drug, and titration protocol, which actually showed global improvement.
The other companies which have presented data in what you are used to, may not have a drug that works in the manner our does, and may not have use titration protocol, making the subgrouping easier to accomplish.
Also our drug response may or may not be linear, and work only in groups with pre-determined conditions.
We know it worked globally based on what has been provided.
Your post are trying to bring to the forefront the question of if we met all endpoints then show me the proof base on what you traditionally call an acceptable analysis compared to other companies and compounds (using the traditional measuring stick).
The traditional measuring stick may not work for our compound and methodology (titrating).
WE MAY NEED TO USE A DIFFERENT INSTRUMENT LIKE (KEM) instead of a traditional measuring stick.
The ODD ratio was the best traditional attempt to explaining the results using what is known and as close as the traditional measuring stick as allowed. I suspect.
We are the exception in my opinion, thus far no company tackling AD has been able to produce the results we have.
You are trying to parallel against the 99% that have failed.
Also maybe the 1% which have had marginal results in gigantic trials. (Note the large n was needed to get these marginal results)
Our drug response and titration method throws a wrench in to all parallels you may have seen.
Note I could be wrong, and we may be dealing with breaking of the law.
But my probability numbers of this are along the range of yours in AA.
Yea the underline part was my intended point, in relation to other investors confidence, well this investor is confident.
Which to this investor is all that matters, as I dont follow the crowd.
If the statement is FALSE, wouldnt the company retract it in order to protect it self from the law?
If the statement is TRUE, is the company required to show right away why it is true? Or can they present it later on in time as long as they do present it. Does the law have something against this?
if the readout of the P2b/3 AD trial was fumbled, then why maintain the statement of ENDPOINTS MET even after the erase both the initial and revised CTAD presentation?
What does a person looks have to do with their abilities to perform their job?
How does good looks get in the way of intelligence?
To me it seems she is monetizing her looks, why should she not?
Do you know if it affects her role in Anavex?
If so, how do you know this information?
I agree! I can't wait!
Amazing how a political science major can be the trusted source for analyzing scientific data of a biotechnology company.
Mind blown, but w.e we seen worse here!
Thank you peeps, not surprised lol
I hope they do throw him under the bus.
Could you please share where you got this from, would love to read about it.
Thank you in advance!
False premise to you too
I was referring to stop losses, from an existing investor.
1 share can trigger 10K shares to sell if a stop loss for the 10K is at the price of the 1 share exercised.
What you may referring to is not placing actual stop losses.
As forcing someone to buy, I have never seen such mechanism except via a limit order, which indicates the person was already willing to buy.
I seriously doubt anyone with too "much money in AVXL", believes they can manipulate the stock price via an opinion based messaged board for retail investors lol.
Even if you convince others to buy, you are convincing other retail investors, that does not move the needle as not many have pre determine purchase prices on the way up.
In the other hand if you force retails to sell, you may be able to trigger stop losses, which are more commonly used.
Causing a cascade of sell order of multiple accounts which may generate more selling volume, for shorts to cover.
How about investors with money on the line?
In happier news today another drug which Adam Fudstertien was betting against gets approved.
Makes perfect sense to me, there is no data during the wait.
Only data available now is the narrative.
It has to be the ignore tool doing its intended job.
See no FUD reply to no FUD.
While awaiting for new data to discuss.
I guess that one flew over your head lol.
No withdraw, I dont even trust my shadow.
Trust the process...
Dont trust the FUD.
Or even more importantly dont trust IR!